References
[1] Kopeć G., Kurzyna M., Mroczek E. et al. Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). J Clin Med. 2020 Jan 8;9(1). pii: E173. [2] Siennicka A., Darocha S., Banaszkiewicz M. et al. Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619891529. [3] Travadi JN, Patole SK: Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol 2003; 36: 529–535. [4] Nair J, Lakshminrusimha S, Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014 Mar;38(2):78-91. doi: 10.1053/j.semperi.2013.11.004. [5] Zalecenia Polskiego Towarzystwa Neonatologicznego. Standardy opieki medycznej nad noworodkiem w Polsce. Wydanie II (2017), zaktualizowane i uzupełnione. [Recommendations of the Polish Society of Neonatology. Standards of medical care for neonates in Poland. Second edition (2017), revised and updated.] Warsaw, PTN&Media-Press Sp. z o.o. 2017, 171-176 [6] Medicinal product dossier: INOmax, INN-nitric oxide [7] Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar VH, et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2009;10:106–12. [8] Walas W, Borszewska- Kornacka M, Świetliński J - Zespół przetrwałego nadciśnienia płucnego u noworodków. Algorytm leczenia. [Persisten pulmonary hypertension of the newborn. A therapeutic algorithm.] MediPage, 2012,11-14 [9] Rawat M., Chandrasekharan P.K., Williams A., Gugino S., Koenigsknecht C., Swartz D., Ma C.X., Mathew B., Nair J., Lakshminrusimha S. Oxygen saturation index and severity of hypoxic respiratory failure. Neonatology. 2015;107:161–166. [7] Khemani RG1, Thomas NJ, Venkatachalam V, Scimeme JP, Berutti T, Schneider JB, Ross PA, Willson DF, Hall MW, Newth CJ; Comparison of SpO2 to PaO2 based markers of lung disease severity for children with acute lung injury. Pediatric Acute Lung Injury and Sepsis Network Investigators (PALISI). Crit Care Med. 2012 Apr;40(4):1309-16. [8] McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2013;14:74–84. [9] Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate. 2006;89:1–5.  [10] McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21:217–22 [11] Ho J.J., Rasa G.: Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007, 18:CD005588. [12] Boo N.Y., Rohana J., Yong S.C. et al.: Inhaled nitric oxide and intravenous magnesium sulphate for the treatment of persistent pulmonary hypertension of the newborn. Singapore Med J 2010, 51:144–150. [13] SatyanLakshminrusimhaMDBobbyMathewMRCPCorinne L.LeachMD, PhD Seminars in Perinatology Volume 40, Issue 3, April 2016, Pages 160-173 [14] Bassler D, Choong K, McNamara PJ, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89: 1-5. [15] Medicinal product dossier: Corotrope